新合成黄腐酚类似物联合顺铂对宫颈癌细胞化疗增敏作用的研究

摘要 目的：探讨新合成黄腐酚类似物联合顺铂对宫颈癌Hela细胞化疗敏感性的影响及其机制。方法：以不同浓度（5、7.5、15、20 μmol/L）黄腐酚类似物处理宫颈癌Hela细胞和正常MRC-5细胞48 h后,MTT实验检测细胞增殖活力并计算出黄腐酚类似物对2种细胞的半数抑制浓度(IC₅₀);采用MTT实验进一步观察IC₅₀最低的黄腐酚类似物联合顺铂对Hela和MRC-5细胞增殖活力的影响,采用流式细胞仪检测Hela细胞周期和凋亡情况,Western blot法检测Hela细胞中凋亡相关蛋白表达变化。结果：黄腐酚类似物a8、a13、b11和b12对宫颈癌Hela细胞增殖均有一定的抑制作用,且a13的IC₅₀值最小;另外,这4种浓度的黄腐酚类似物对正常MRC-5细胞有轻微的抑制作用,且a13的IC50值最大。与对照组比较,顺铂组、a13组、顺铂+a13组中正常MRC-5细胞存活率差异均无统计学意义（P<0.05）,但顺铂组、a13组和顺铂+a13组中宫颈癌Hela细胞存活率、G2/M期细胞百分比和B淋巴细胞瘤-2基因（Bcl-2）蛋白表达水平均明显降低,而G0/G1期细胞百分比、细胞凋亡率和细胞中细胞色素C（Cyt-c）、Bcl-2关联X蛋白（Bax）、活化的半胱氨酸天冬氨酸蛋白酶3（Cleaved Caspase-3）、活化的半胱氨酸天冬氨酸蛋白酶9（Cleaved Caspase-9）蛋白表达水平均明显升高,且顺铂+a13组中上述指标变化幅度明显大于顺铂组、a13组（P<0.05）。结论：黄腐酚类似物与顺铂联合可协同抑制宫颈癌Hela细胞增殖,表现良好的化疗增敏效果,其作用机制可能与阻滞细胞周期进程和调控凋亡相关蛋白表达促进细胞凋亡有关。     

花生四烯酸通过COX-2酶代谢氧化失活PTEN促进结直肠癌生长

摘要 目的：本研究旨在阐明过表达COX-2的结直肠癌中花生四烯酸代谢与PTEN及其下游通路的相互关系。方法：利用过表达COX-2结直肠癌细胞系CT26和Apc ^Min/+小鼠腺瘤模型,联合花生四烯酸、COX-2抑制剂NS-398和COX-2基因敲除的干预,采用流式细胞仪检测细胞凋亡、细胞周期及活性氧的产生;Transwell和克隆形成试验观察细胞的迁移和增殖能力;Western blot和免疫组化检测PTEN及其下游相关蛋白的表达。结果：花生四烯酸通过COX-2酶代谢产生活性氧并失活PTEN抑癌基因表达,从而激活PI3K-AKT蛋白促进CT26结直肠癌细胞迁移和增殖,抑制细胞凋亡;而COX-2抑制剂NS-398阻止了花生四烯酸在CT26结直肠癌细胞中的恶性生物学行为。同时,在COX-2基因敲除Apc ^Min/+小鼠腺瘤组织中,减弱了氧化应激水平,增加了PTEN表达,抑制了PI3K-AKT磷酸化,进一步抑制腺瘤生长,提高小鼠生存率。结论：花生四烯酸通过COX-2酶代谢产生活性氧下调PTEN活性,并激活PI3K-AKT促进结直肠癌生长;COX-2抑制剂可间接促进PTEN表达,抑制结直肠癌生长,能够作为CRC的潜在治疗靶点。     

HOXD9促进肺癌发生发展的生物学作用及初步机制

摘要 目的：探究同源盒基因HOXD9在H3255、H2170肺癌细胞株中的生物学作用及作用机制。方法：构建HOXD9过表达稳转H3255、H2170肺癌细胞株,通过CCK-8、克隆形成、小鼠皮下瘤实验检测HOXD9对肺癌细胞增殖的影响;利用transwell、基质胶实验检测HOXD9对肺癌细胞迁移及侵袭的影响;采用彗星实验、磷酸化组蛋白H2AX（γH2AX）免疫荧光染色检测HOXD9对肺癌细胞DNA损伤的影响;通过流式细胞术检测HOXD9对肺癌细胞凋亡的影响;通过qRT-PCR、western blot、luciferase、ChIP、rescue实验探究HOXD9在肺癌中促癌的作用机制。结果：CCK-8、克隆形成、小鼠皮下瘤实验显示HOXD9可促进肺癌细胞增殖;transwell实验表明HOXD9可促进肺癌细胞迁移;基质胶实验显示HOXD9可促进肺癌细胞侵袭;彗星实验与γH2AX免疫荧光染色提示HOXD9可抑制肺癌细胞DNA损伤;流式细胞术显示HOXD9可抑制肺癌细胞凋亡。HOXD9可通过转录上调肺癌细胞中增殖细胞核抗原PCNA的表达水平。结论：HOXD9可通过促进PCNA的转录介导肺癌细胞的增殖、迁移、侵袭,抑制肺癌细胞DNA损伤及凋亡。     

MiR-150-5p靶向TP53对结直肠癌细胞侵袭和增殖的影响

摘要 目的：探索miR-150-5p靶向调控TP53基因对结直肠癌（colorectal cancer, CRC）在临床和生物学的相关性,研究miR-150-5p调控TP53基因在结直肠癌细胞增殖和侵袭病变中的作用。方法：收集临床手术切除并病理证实的结直肠癌患者的手术及血浆样本（结直肠癌和癌旁组织）60例,另选取癌旁正常粘膜10例,腺瘤30例。根据瘤体直径分为肿瘤＞5 cm（n=30）和≤5 cm（n=30）。qRT-PCR法测定样本中miR-150-5p表达,荧光素酶活性测定以确定TP53是否为miR-150-5p的靶基因。使用SW480细胞株,进行Transwell小室检测细胞侵袭能力,CCK-8检测细胞增值能力,对miR-150-5p进行生物信息学分析。结果：TP53是miR-150-5p的下游基因。癌组织及血浆中miR-150-5p表达量低于癌旁组织,直径＞5 cm瘤体中的miR-150-5p表达量显著低于直径≤5 cm瘤体,Ⅰ-Ⅱ期结直肠癌组织中的miR-150-5p表达显著高于Ⅲ-Ⅳ期（P＜0.05）。上调miR-150-5p后,细胞中TP53表达下降,下调miR-150-5p后,TP53表达升高;CCK-8增殖试验显示细胞中miR-150-5p过表达组抑制细胞增殖（P＜0.05）。结论：MiR-150-5p在结直肠癌组织和细胞中显著低表达,miR-150-5p通过靶向调节TP53抑制人CRC细胞的侵袭和增殖,有望成为结直肠癌治疗的新靶点。     

miR-155-TP53INP1调节轴在结直肠癌化疗药物敏感性中的作用机制

摘要 目的：初步揭示miR-155通过靶向调节TP53INP1表达水平影响结直肠癌细胞对5-FU化疗敏感性。方法：将人结肠直肠癌细胞系HCT116进行培养,提取细胞总RNA后,采用miR-155逆转录特异性引物构建反转录体系进行PCR扩增,通过qRT-PCR检测miR-155在5-FU耐药细胞HCT116/FU及敏感细胞株HCT116中的表达情况;取对数生长期细胞,分别转染miR-155mimics、miR-155抑制剂、miR-155阴性对照后,采用CCK-8法检测miR-155对细胞5-FU药物敏感性的影响,双荧光素酶报告基因系统验证miR-155与TP53INP1的靶基因关系,Western blot检测miR-155对 TP53INP1表达的影响。结果：miR-155在HCT116 /Fu细胞中的表达量是HCT116细胞的7.25倍;在相同5-FU浓度时,HCT116+阴性对照的细胞生长抑制率均高于HCT116+mimics、半数抑制浓度显著低于HCT116+mimics,差异均具有统计学意义(P＜0.05);TP53INP1是miR-155的靶基因,能显著降低野生型TP53INP1 3''-UTR的荧光素酶活性;转染miR-155 mimics后,TP53INP1的相对表达量显著下降,转染miR-155抑制剂后,TP53INP1的相对表达量显著升高,差异均具有统计学意义(P＜0.05)。结论：miR-155水平升高使HCT116细胞对5-FU的敏感性降低,miR-155可能通过靶向调节TP53INP1的表达水平,从而影响结直肠癌细胞对5-FU的敏感性。     

利用CRISPR/Cas9技术靶向KRAS或TP53突变抑制SW620细胞的增殖

摘要 目的：运用CRISPR/Cas9基因编辑工具研究靶向SW620细胞系中KRAS或TP53突变对细胞增殖活性的影响。方法：针对SW620细胞中KRAS和TP53的突变位点设计sgRNA,并利用TIDE法检测sgRNA的切割效率。通过细胞增殖实验检测靶向KRAS或TP53突变后SW620细胞增殖活性的改变,并应用Annexin V-FITC/PI双染法检测细胞凋亡水平的变化。结果：分别构建了靶向SW620细胞系中KRAS和TP53突变的sgRNA质粒,并通过TIDE分析验证了sgRNA的内源切割效率;细胞增殖实验及细胞凋亡检测显示,靶向突变的KRAS或TP53基因后,SW620细胞增殖活性明显减弱,凋亡水平明显升高（P<0.05）。结论：本研究基于CRISPR/Cas9技术实现了对SW620细胞系中突变的KRAS和TP53的基因编辑,发现靶向KRAS或TP53突变能够明显抑制SW620细胞的增殖活性并促进细胞凋亡,为结直肠癌相关靶点治疗提供了体外实验依据。     

褪黑素联合MPA抑制子宫内膜异常增生的作用及机制研究

摘要 目的：探索褪黑素联合MPA（醋酸甲羟孕酮）对子宫内膜异常增生细胞增殖活性的抑制作用及其机制。方法：取分化良好的子宫内膜增生细胞株Ishikawa和内膜癌细胞株ECC1于适宜条件培养,加入褪黑素、MPA单独或者联合处理48 h后,检测子宫内膜细胞株的增殖活性。收集褪黑素、MPA单独或者联合处理48 h后的子宫内膜增生细胞株Ishikawa细胞,提取细胞内的蛋白,检测人20α-羟基类固醇脱氢酶（AKR1C1）的表达情况。结果：褪黑素和MPA联合使用后对子宫内膜异常增生细胞的抑制作用明显高于褪黑素或MPA单独使用。褪黑素和MPA可抑制AKR1C1的表达,二者联合使用对AKR1C1的抑制高于两者单独使用。结论：褪黑素可提高子宫内膜异常增生细胞对MPA的敏感性,降低MPA的使用剂量,同时抑制AKR1C1的表达,使孕酮的代谢速率降低。褪黑素与MPA联合使用给子宫内膜增生和内膜癌的治疗策略带来新的思路。     

lncRNA XIST-miR137-ATG5调节细胞自噬功能在肠癌细胞5-氟胞嘧啶耐药性中的作用

摘要 目的：本文旨在研究长链非编码RNA XIST-miR137-ATG5的相互作用,同时探讨其调节细胞自噬功能与肠癌细胞5-氟胞嘧啶敏感性的关系。方法：实时聚合酶链反应(real time PCR)检测XIST与miR-137在肠癌细胞中的表达;采用脂质体转染法将si-XIST,miR-137转染入肠癌SW480及HCT116细胞中。采用CCK-8检测瞬时转染si-XIST对肠癌细胞增殖及5-FU敏感性的影响;并利用双荧光素酶报告实验检测miR-137与XIST, miR-137与ATG5相互关系。Western blot方法检测XIST- miR137- ATG5对细胞自噬的影响。结果：与正常结肠细胞FHC比较, XIST在结肠癌细胞系明显高表达,miR-137在结肠癌细胞系明显低表达。与阴性对照组比较,转染si-XIST后,SW480及HCT116细胞增殖能力明显受到抑制,对F-5U的敏感性增强,且抑制自噬蛋白Beclin-1及LC3II/LC3 I的表达。miR-137可与XIST,ATG5 3''UTR结合,抑制XIST和ATG5的表达及功能。在结肠癌SW480细胞中共转染miR-137 inhibitor或过表达ATG5可逆转XIST沉默引起的5-FU耐药,同时可逆转因XIST沉默引起的自噬蛋白表达的抑制。结论：LncRNA XIST或可通过调控mir137-ATG促进结直肠癌细胞SW480自噬从而提高其对5-FU的耐药,针对其这一机制,可为将来针对结肠癌的靶向治疗提供一定的实验基础。     

N-豆蔻酰化转移酶在乳腺癌组织中的表达及作用研究

摘要 目的：研究N-豆蔻酰化转移酶1（NMT1）和2（NMT2）在乳腺癌组织中的表达及对乳腺癌细胞生物学作用。方法：ELISA检测NMT1和NMT2在40例乳腺癌组织中含量,免疫组化证实其表达。小RNA干扰技术敲减乳腺癌细胞MCF-7及BT-474中NMT1和NMT2表达水平。CCK-8及Transwell小室穿膜试验检测NMT1和NMT2敲减前后细胞增殖及转移能力变化。结果：NMT1及NMT2在发生淋巴结转移、III/IV期患者的乳腺癌组织中表达显著升高（P<0.01）。利用CCK-8检测发现NMT1或NMT2敲减48h后乳腺癌细胞BT-474、MCF-7增殖活性较对照组细胞显著减弱（P<0.0001）。Transwell小室穿膜试验检测发现,NMT1或NMT2敲减组细胞较对照组细胞,穿膜细胞数显著减低（P<0.01）。结论：NMT1及NMT2在乳腺癌的发生、发展过程中起到关键作用,敲减NMT1及NMT2可削弱乳腺癌细胞增殖和转移能力。靶向抑制NMT1及NMT2有望成为干预乳腺癌的重要分子靶点。     

顺铂联合VEGF抗体对食管癌移植瘤小鼠免疫调节以及癌细胞增殖和肺转移的影响

摘要 目的：研究顺铂联合血管内皮生长因子（vascular endothelial growth factor,VEGF）治疗对食管癌移植瘤小鼠免疫功能、癌细胞增殖以及肺转移的影响。方法：30只BALB/c小鼠通过皮下注射食管癌移植瘤模型。一周后,30只食管癌移植瘤模型小鼠被随机均分为3组,即模型组、顺铂组和联合组。模型组不进行治疗,顺铂组腹腔注顺铂治疗,联合组腹腔注射顺铂联合尾静脉注射VEGF抗体进行治疗,共治疗7周。比较各组小鼠体重,食管癌移植瘤体积和重量,卵巢癌细胞肺组织转移结节数、癌细胞转移面积和转移病灶总数,以及食管癌移植瘤外周血CD4⁺、CD8⁺以及CD4⁺/CD8⁺ T淋巴细胞比例。结果：（1）顺博组和联合组小鼠体重均显著高于对照组,而联合组小鼠体重显著高于顺铂组（P<0.05）;（2）顺铂组和联合组小鼠CD4+和CD8+细胞比例均显著低于对照组（P<0.05）,而CD4⁺/CD8⁺却显著高于对照组（P<0.05）;（3）联合组小鼠CD4⁺和CD8⁺细胞比例均显著高于对照组（P<0.05）,而CD4⁺/CD8⁺却显著低于顺铂组（P<0.05）;（4）顺铂组和联合组小鼠食管癌肿瘤组织体积和重量,肺转移结节数、转移面积和转移病灶数均显著低于对照组（P<0.05）,而联合组小鼠显著低于顺铂组（P<0.05）。结论：VEGF抗体可以显著增强顺铂在体内对食管癌的抗癌特性,并有助于增强食管癌移植瘤小鼠免疫功能、抑制癌细胞体内增殖和肺部转移。     

去乙酰化酶抑制剂TSA介导Ku70乙酰化对结肠癌HT29细胞凋亡和自噬的影响

目的:探讨不同浓度组蛋白去乙酰化酶抑制剂TSA对结肠癌HT29细胞的增殖、凋亡和自噬影响及其机制研究。方法:取对数生长期人结肠癌HT29细胞,采用MTT法检测不同浓度TSA处理对其细胞活力影响,并根据IC50值确定适宜给药浓度;采用流式细胞术检测不同浓度TSA处理后结肠癌HT29细胞的凋亡情况;Western blot验证空白对照组与TSA给药处理组中凋亡标志蛋白Ku70、acetrl-Ku70、Caspase3、Bax、Bcl-2和自噬标志蛋白LC3和Beclin1的表达。结果:MTT法实验结果表明TSA对结肠癌HT29细胞具有时间和浓度依赖性抑制作用,根据IC50=1.12μM,本研究中TSA的给药浓度为0.5μM和1μM;流式细胞凋亡检测结果表明TSA能够显著促进结肠癌HT29细胞凋亡,且其促凋亡作用存在浓度依赖性;此外,Western blot检测结果证实,与空白对照组相比,TSA给药处理可显著上调上述细胞中acetrl-Ku70以及促凋亡蛋白Caspase3、Bax和自噬标志蛋白LC3和Beclin1的表达,下调抗凋亡蛋白Bcl-2的表达(P<0.05)。结论:组蛋白去乙酰化酶抑制剂(TSA)的体外抗结肠癌细胞的增殖、促进细胞凋亡和自噬作用与其上调Ku70蛋白乙酰化密切相关,有望成为临床潜在抗癌靶点。     

Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines – An Isobolographic Analysis

Histone deacetylase inhibitors (HDIs) are promising anticancer drugs, which inhibit proliferation of a wide variety of cancer cells including breast carcinoma cells. In the present study, we investigated the influence of valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA, vorinostat), alone or in combination with cisplatin (CDDP) on proliferation, induction of apoptosis and cell cycle progression in MCF7, T47D and MDA-MB-231 human breast carcinoma cell lines. The type of interaction between HDIs and CDDP was determined by an isobolographic analysis. The isobolographic analysis is a very precise and rigorous pharmacodynamic method, to determine the presence of synergism, addition or antagonism between different drugs with using variety of fixed dose ratios. Our experiments show that the combinations of CDDP with SAHA or VPA at a fixed-ratio of 1:1 exerted additive interaction in the viability of MCF7 cells, while in T47D cells there was a tendency to synergy. In contrast, sub-additive (antagonistic) interaction was observed for the combination of CDDP with VPA in MDA-MB-231 “triple-negative” (i.e. estrogen receptor negative, progesterone receptor negative, and HER-2 negative) human breast cancer cells, whereas combination of CDDP with SAHA in the same MDA-MB-231 cell line yielded additive interaction. Additionally, combined HDIs/CDDP treatment resulted in increase in apoptosis and cell cycle arrest in all tested breast cancer cell lines in comparison with a single therapy. In conclusion, the additive interaction of CDDP with SAHA or VPA suggests that HDIs could be combined with CDDP in order to optimize treatment regimen in some human breast cancers.     

紫丁香苷调控PI3K/Akt/mTOR信号通路诱导乳腺癌细胞凋亡的研究

目的 研究紫丁香苷的抗乳腺癌作用及分子机制，为紫丁香苷的临床应用提供理论依据。方法 MTT检测紫丁香苷对乳腺癌细胞增殖的抑制作用；台盼蓝、TUNEL和Annexin V-FITC/PI染色检测细胞的凋亡状况，Western bolt检测Caspase-3的活化情况，判断细胞凋亡是否发生；检测凋亡相关蛋白B淋巴细胞瘤2（Bcl-2）的表达，结合JC-1染色探讨紫丁香苷对线粒体凋亡途径的影响；运用PI3K激动剂Recilisib做对比，qRT-PCR和Western bolt检测紫丁香苷调控PI3K/Akt/mTOR通路诱导癌细胞凋亡的作用。结果 紫丁香苷对乳腺癌细胞的增殖具有时间和剂量依赖的抑制作用，能诱导癌细胞发生凋亡。进一步研究发现，紫丁香苷处理后，细胞内Caspase-3被激活，Bcl-2表达下降，线粒体膜电位明显丧失，PI3K、Akt和mTOR的mRNA与蛋白质水平表达无明显变化，但蛋白质磷酸化水平明显下降；Recilisib处理后部分抵消了紫丁香苷对乳腺癌细胞凋亡的作用。结论 紫丁香苷对乳腺癌细胞MDA-MB-231和MCF-7具有良好的抑制作用，其通过抑制PI3K/Akt/mTOR信号通路的活化来抑制细胞增殖并诱导细胞发生线粒体途径的凋亡。紫丁香苷是具有开发潜力的抗乳腺癌药物。     

Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001

AimsTo analyze the combined impact of the histone deacetylase (HDAC) inhibitor valproic acid (VPA) and the mammalian target of rapamycin (mTOR) inhibitor RAD001 on prostate cancer cell growth.Main methodsPC-3, DU-145 and LNCaP cells were treated with RAD001, VPA or with an RAD001–VPA combination for 3 or 5 days. Tumor cell growth, cell cycle progression and cell cycle regulating proteins were then investigated by MTT assay, flow cytometry and Western blotting, respectively. Effects of drug treatment on cell signaling pathways were determined.Key findingsSeparate application of RAD001 or VPA distinctly reduced tumor cell growth and impaired cell cycle progression. Significant additive effects were evoked when both drugs were used in concert. Particularly, the cell cycle regulating proteins cdk1, cdk2, cdk4 and cyclin B were reduced, whereas p21 and p27 were enhanced by the RAD001–VPA combination. Signaling analysis revealed deactivation of EGFr, ERK1/2 and p70S6k. Phosphorylation of Akt was diminished in DU-145 but elevated in PC-3 and LNCaP cells.SignificanceThe RAD001–VPA combination exerted profound antitumor properties on a panel of prostate cancer cell lines. Therefore, simultaneous blockage of HDAC and mTOR related pathways should be considered when designing novel therapeutic strategies for treating prostate carcinoma.     

Enhanced suppression of proliferation and migration in highly-metastatic lung cancer cells by combination of valproic acid and coumarin-3-carboxylic acid and its molecular mechanisms of action

Valproic acid (VPA) as a broad-spectrum inhibitor of histone deacetylase, has been used in cancer therapy. Recently, the combination of VPA with other anticancer agents has been considered as a useful and necessary strategy to inhibit tumor growth and progression. The coumarin derivates from natural plants have been shown to be the promising natural anticancer agents. However, no literature is available on the anticancer effects of the combination of VPA and coumarin-3-carboxylic acid (HCCA). Here we show that this combination significantly increases inhibitory effects against the proliferation and migration in highly-metastatic lung cancer cells by inducing apoptosis and cell cycle arrest as well as regulating related protein expressions. Our results indicate that this combination of VPA with HCCA not only enhances the protein levels of Bax, cytosolic cytochrome c, caspase-3 and PARP-1 but also reduces the protein expressions of Bcl-2, cyclin D1 and NF-κB as well as inhibits the phosphorylation and expressions of Akt, EGFR, VEGFR2 and c-Met in the cancer cells. Our results suggest that the combination of VPA with HCCA suppresses the proliferation and migration of lung cancer cells via EGFR/VEGFR2/c-Met-Akt-NF-κB signaling pathways; this combination may have a wide therapeutic and/or adjuvant therapeutic application in the treatment of lung cancer.     

Selenium potentiates the anticancer effect of cisplatin against oxidative stress and calcium ion signaling-induced intracellular toxicity in MCF-7 breast cancer cells: involvement of the TRPV1 channel

Background: In breast cancers, calcium signaling is a main cause of proliferation and apoptosis of breast cancer cells. Although previous studies have implicated the transient receptor potential vanilloid 1 (TRPV1) cation channel, the synergistic inhibition effects of selenium (Se) and cisplatin in cancer and the suppression of ongoing apoptosis have not yet been investigated in MCF-7 breast cancer cells. This study investigates the anticancer properties of Se through TRPV1 channel activity in MCF-7 breast cancer cell line cultures when given alone or in combination with cisplatin. Materials: The MCF-7 cells were divided into four groups: the control group, the Se-treated group (200?nM), the cisplatin-treated group (40?μM) and the Se?+?cisplatin-treated group. Results: The intracellular free calcium ion concentration and current densities increased with TRPV1 channel activator capsaicin (0.01?mM), but they decreased with the TRPV1 blocker capsazepine (0.1?mM), Se, cisplatin, and Se?+?cisplatin incubations. However, mitochondrial membrane depolarization, apoptosis, and the caspase 3, and caspase 9 values increased in the Se-treated group and the cisplatin-treated group, although Western blot (procaspase 3 and 9) results and the cell viability levels decreased with the Se and Se?+?cisplatin treatments. Apoptosis and caspase-3 were further increased with the Se?+?cisplatin treatment. Intracellular reactive oxygen species production increased with the cisplatin treatment, but not with the Se treatment. Conclusion: This study’s results report, for the first time, that at a cellular level, Se and cisplatin interact on the same intracellular toxic cascade, and the combination of these two drugs can result in a remarkable anticancer effect through modulation of the TRPV1.     

RNA结合蛋白QKI-5对乳腺癌细胞MCF-7增殖的影响研究

目的:检测RNA结合蛋白QKI-5在乳腺癌细胞中的表达水平以及对癌细胞增殖能力的抑制作用。方法:通过免疫印迹实验检测QKI-5在不同乳腺癌细胞株中的表达水平,通过慢病毒感染构建能够稳定过表达QKI-5基因的细胞株,使用MTT,流式细胞仪检测细胞周期来观察过表达QKI-5对细胞增殖能力及周期的影响。结果:MCF-7细胞在三株乳腺癌细胞中QKI-5表达水平相对最低,MTT实验结果显示与对照相比,过表达QKI-5的MCF-7细胞增殖能力出现显著降低P0.05,同时细胞周期检测显示过表达QKI-5的MCF-7细胞组出现了明显的G1期阻滞,进入S期G2/M期细胞减少。结论:在乳腺癌中QKI-5的高表达可能通过抑制癌细胞周期致使细胞增殖变缓,从而导致肿瘤生长受限。     

Anticancer Effects of Valproic Acid on Esophageal Stem-like Carcinoma Cells

Valproic acid (VPA) is a histone deacetylase inhibitor that has been an object of interest to clinicians for its promising potency in cancer therapy, as it induces apoptosis and differentiation, and enhances of chemotherapy sensitivity. Esophageal squamous cell carcinoma (ESCC) is a malignant disease with growing incidence and low survival rate. Due to limited information on VPA activity in ESCC cells, we aimed to determine effects of VPA on chemotherapy responsiveness and expression of malignant markers in ESCC stem-like cells. Upon coadministration of non-toxic VPA + cisplatin (DDP), paclitaxel and 5-fluorouracil, viability of KYSE30 cells was assessed, and induced apoptosis was evaluated by DAPI staining, DNA laddering and flow cytometry. In addition, real time RT-PCR was performed to study changes in the expression of P21, CD44 and BMI-1 upon treatments. MTT test demonstrated that VPA significantly (P < 0.05) increased toxicity of DDP, which was confirmed by DNA laddering, flow cytometry analysis and significant (P < 0.05) overexpression of P21. Moreover, real time RT-PCR results indicated significant (P < 0.05) down regulation of CD44 and BMI-1 after VPA administration. Present attempt provided evidence, for the first time, that VPA not only improved responsiveness of esophageal stem-like cancer cells to DDP, also negatively regulated cancer stem cells markers in these cells.